A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Luspatercept (Primary)
- Indications Anaemia; Myelofibrosis
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 31 Jan 2018 Planned End Date changed from 29 Jun 2019 to 21 Nov 2023.
- 31 Jan 2018 Planned primary completion date changed from 8 Jun 2019 to 15 Jun 2019.
- 28 Aug 2017 Planned End Date changed from 7 Nov 2023 to 29 Jun 2019.